Homepage > Company > Media > Pharma News > 2018 > Aurobindo gets FDA approval for generic Arixtra

Aurobindo gets FDA approval for generic Arixtra

The Food and Drug Administration recently approved Aurobindo’s generic of Mylan’s Arixtra (fondaparinux sodium) injection. The company has planned January launch for the drug, which is indicated to prevent deep vein thrombosis.

Aurobindo’s generic will be available in single-dose prefilled syringes of 2.5 mg/0.5 ml, 5 mg/0.4 ml, 7.5 mg/0.6 ml and 10 mg/0.8 ml. The product’s market size was $73 million for the 12 months ended October 2017, according to IQVIA data.

January 16, 2018

https://www.drugstorenews.com/

Read also

EC approves AstraZeneca’s Fasenra for EGPA treatment

The European Commission (EC) has approved AstraZeneca‘s Fasenra (benralizumab) as an add-on therapy for adults with relapsing or refractory eosinophilic granulomatosis with polyangii...

Genprex reports positive preclinical gene therapy data

Genprex, Inc., a clinical-stage gene therapy company, announced positive preclinical results for its lead drug candidate, Reqorsa® (quratusugene ozeplasmid) Gene Therapy, at the recent EORTC-...

Astellas withdraws Europe ACP application for AMD treatment

Astellas Pharma has announced the withdrawal of its marketing authorisation application for IZERVAY (avacincaptad pegol, ACP) intravitreal solution to treat geographic atrophy (GA) sec...

New report demands greater understanding of the impact of change on academia

Digital Science, a technology company serving stakeholders across the research ecosystem, is today calling for greater awareness of the impact that a myriad of fast-developing technologies are having ...